Literature DB >> 12380062

Update on botulinum toxin for facial aesthetics.

Jennifer Clay Cather1, J Christian Cather, Alan Menter.   

Abstract

The use of botulinum toxin has revolutionized the treatment of facial lines with an incomparable safety record over the past 14 years. The most common used injection sites are shown in Fig. 9. With the recent FDA approval for Botox in the treatment of glabellar lines, its use will likely increase dramatically. It is essential that practitioners have a detailed and specific knowledge of the facial and neck musculature to be injected to minimize untoward side effects, especially in the early days of new users' learning curve. The specifics of the dilutions and units per amount used for the various different commercial forms of botulinum toxin types A and B need to be understood fully and standardized together with the potential for antigenicity with the higher protein load of type B. In addition, specific indications for the use of botulinum toxin as adjunctive therapy for specific facial surgical procedures (i.e., blepharoplasty, surgical brow lift, and laser resurfacing) will become better understood. [figure: see text] Finally, even though the anatomy of the facial musculature is well described, individual differences in men and women, in different population groups, and in tissue qualities, such as turgor and elasticity [87], are important factors to be considered before undertaking botulinum toxin injections. It is likely that the use of specific measuring devices, such as digital imaging, will further help define the use of botulinum toxin for different muscle groups and facial aesthetic indications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12380062     DOI: 10.1016/s0733-8635(02)00043-8

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  8 in total

1.  Martin Alan Menter, MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Martin Alan Menter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-04

Review 2.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Botulinum toxin type a for the treatment of hyperkinetic lines of the face.

Authors:  Dinesh Singh Chauhan; K M Cariappa; Yadavalli Guruprasad
Journal:  J Maxillofac Oral Surg       Date:  2012-08-28

4.  Botulinum toxin for the treatment of hyperfunctional lines of the forehead.

Authors:  Sathigrama Malegowda Sunil; B Ganesh Babu; Soma Deepthi; Anusha Channabasappa Veerabhadrappa; Suneel V Vadavadagi; Prashant Punde
Journal:  J Int Soc Prev Community Dent       Date:  2015 Jul-Aug

Review 5.  Botulinum toxin the poison that heals: A brief review.

Authors:  Shubha Ranjan Dutta; Deepak Passi; Mahinder Singh; Purnima Singh; Sarang Sharma; Abhimanyu Sharma
Journal:  Natl J Maxillofac Surg       Date:  2016 Jan-Jun

6.  The use of stem cells in aesthetic dermatology and plastic surgery procedures. A compact review of experimental and clinical applications.

Authors:  Maciej Nowacki; Tomasz Kloskowski; Katarzyna Pietkun; Maciej Zegarski; Marta Pokrywczyńska; Samy L Habib; Tomasz Drewa; Barbara Zegarska
Journal:  Postepy Dermatol Alergol       Date:  2017-12-31       Impact factor: 1.837

7.  A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.

Authors:  Doris M Snow; Ronald R Cobb; Juan Martinez; Isaac Finger-Baker; Laura Collins; Sara Terpening; Emily S Syar; Nancy Niemuth; Dean Kobs; Roy Barnewall; Shauna Farr-Jones; James D Marks; Milan T Tomic
Journal:  Toxins (Basel)       Date:  2021-01-05       Impact factor: 4.546

Review 8.  Cosmetic use of botulinum toxin type A in the elderly.

Authors:  Christine M Cheng
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.